Related Experiment Video
Updated: Jul 17, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Haemochromatosis gene (HFE) polymorphisms and migraine: an association study
I Rainero1, E Rubino, C Rivoiro
1Neurology II, Headache Centre, Department of Neuroscience, University of Torino, Torino, Italy. irainero@molinette.piemonte.it
Iron metabolism may influence migraine. This study found the HFE H63D polymorphism may affect migraine onset age and attack frequency, suggesting it as a modifying genetic factor.
Area of Science:
- Neuroscience
- Genetics
- Human Physiology
Background:
- Iron metabolism is implicated in migraine pathogenesis.
- The haemochromatosis gene (HFE) plays a role in iron regulation.
- Genetic variations in HFE may influence migraine susceptibility or clinical presentation.
Purpose of the Study:
- To investigate the association between HFE gene polymorphisms (C282Y and H63D) and migraine in an Italian cohort.
- To determine if HFE genotypes modify migraine occurrence and clinical features.
Main Methods:
- Case-control study design.
- Genotyping of HFE C282Y and H63D polymorphisms in 256 migraine patients and 237 healthy controls.
- Analysis of allele and genotype frequencies and correlation with clinical features.
Main Results:
- No significant difference in HFE C282Y or H63D allele/genotype frequencies between migraine patients and controls.
- Migraine patients with the HFE H63D DD genotype exhibited a later age at onset.
- The HFE H63D DD genotype was associated with a higher number of migraine attacks.
Conclusions:
- The HFE gene is unlikely to be a major causative gene for migraine.
- The H63D polymorphism of the HFE gene may act as a modifying genetic factor influencing migraine clinical characteristics, such as age at onset and attack frequency.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Cardiomyopathy III: Hypertrophic Cardiomyopathy